Related Experiment Video
Updated: Jul 25, 2026

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
Published on: July 3, 2013
Bendamustine-induced nephrogenic diabetes insipidus - A case report
Audrey Desjardins1, Viviane Le-Nguyen1, Léa Turgeon-Mallette1
1Faculty of Pharmacy, Université de Montréal, Montreal, Canada.
Introduction:
In patients with relapsed or refractory lymphoma, high-dose chemoimmunotherapy with subsequent autologous hematopoietic cell transplantation (HCT) is a standard of care. Bendamustine, an alkylating agent, is used in the BeEAM (bendamustine, etoposide, cytarabine, melphalan) protocol for conditioning therapy before autologous HCT in patients with relapsed or refractory lymphoma who are eligible for transplant. There is no consensus regarding an optimal salvage regimen and the approach varies according to toxicity.
Case Report:
We present a case of partial nephrogenic diabetes insipidus after receiving bendamustine, as part of the BeEAM protocol.Management and outcome: The patient was managed with parenteral fluid administration and intranasal desmopressin before the condition resolved on its own.
Discussion:
We summarize published reports of bendamustine-induced diabetes insipidus.
More Related Videos
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Nephrotic Syndrome II : Assessment and Medical Management
Diabetes Insipidus I: Introduction
Diabetes Insipidus II: Pathophysiology
Type I Diabetes III: Clinical Manifestations
Diabetic Nephropathy

